RolfoLab
@rolfolab.bsky.social
190 followers 69 following 24 posts
Liquid Biopsy & Biomarkers Lab 🩸 🧬 🏫 The James Comprehensive Cancer Center - The Ohio State University
Posts Media Videos Starter Packs
Reposted by RolfoLab
islb.info
Early Registration Is Open for #ISLB25!

Register by October 10, 2025, to take advantage of discounted rates. Full In-Person Registration Includes access to all Scientific Sessions (except ticketed sessions), entry to the Exhibition Hall, and more!

Register now at 2025.islb.info/lrdo
Reposted by RolfoLab
robertoboreamd.bsky.social
🚨Excited to represent the @islb.info at #ASCO25!

Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities!
Got questions about the society? We’ve got answers. Come to connect!🩸

@ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social
Reposted by RolfoLab
christianrolfo.bsky.social
Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social
rolfolab.bsky.social
5/5
Both TBx & LBx are suitable & complementary for METex14 skipping detection.
✅LBx Pros: Minimally invasive, rapid, feasible for ill patients/inaccessible tumors, boosts enrollment
❌ LBx Cons: Can have lower sensitivity (false negatives) with low ctDNA shedding
rolfolab.bsky.social
4/5
Further analysis: Among TBx-positive patients with matched LBx results, those who were LBx-negative showed trends for longer DOR, PFS, and OS compared to those who were also LBx-positive. (Fig3)
rolfolab.bsky.social
3/5
Why the difference in time-dependent outcomes? LBx-positive patients had:
➡️ Higher baseline radiographic tumor burden
➡️ More extensive disease
➡️ Worse baseline health-related quality of life & symptoms.
rolfolab.bsky.social
While ORRs were similar (TBx-pos 54.3% vs. LBx-pos 51.7%), time-dependent outcomes trended shorter in LBx-positive patients. 📉 mPFS: 13.7 mo (TBx) vs. 8.9 mo (LBx). 📉 Median OS: 22.9 mo (TBx) vs. 17.6 mo (LBx)
rolfolab.bsky.social
New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social
rolfolab.bsky.social
Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism”
@OSUCCC_James

@osuwexmed.bsky.social
@christianrolfo.bsky.social
@theaacr.bsky.social
pbs.twimg.com/media/Gpay9i...
Reposted by RolfoLab
robertoboreamd.bsky.social
Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬

LB is reshaping cancer care 💥
Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/

@islb.info @christianrolfo.bsky.social @rolfolab.bsky.social
Reposted by RolfoLab
christianrolfo.bsky.social
Congrats Roberto! And welcome to @rolfolab.bsky.social !!!
robertoboreamd.bsky.social
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
Reposted by RolfoLab
robertoboreamd.bsky.social
Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬

Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social

Exciting discussions shaping the future of #lungcancer testing! 📚
Reposted by RolfoLab
robertoboreamd.bsky.social
Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅

Grateful for the chance to meet with exceptional people 👐

@stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social
Reposted by RolfoLab
yukselurun.bsky.social
Navigating the future of #LiquidBiopsy with @christianrolfo.bsky.social at #poles25
From screening to resistance tracking—MRD is reshaping how we detect, treat, and monitor cancer.
Tissue vs liquid? It’s not a battle—it’s a partnership.
@rolfolab.bsky.social @islb.info @oncoalert.bsky.social
Reposted by RolfoLab
robertoboreamd.bsky.social
As always, an insightful presentation by @UmbertoMalapelle

➡️ "From single gene testing to CGP." 🔬✨
at #ELCC25 @myesmo.bsky.social

We must continue this path to improve treatment selection!

@islb.info #precisiononcology #lungcancer

⬇️ Key message
Reposted by RolfoLab
robertoboreamd.bsky.social
Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights!

@osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social
@unige
Reposted by RolfoLab
islb.info
📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸
Read more: doi.org/10.1016/j.crit…#LiquidBiopsysy
@christianrolfo.bsky.soci
al
Reposted by RolfoLab
robertoboreamd.bsky.social
🚨 Out in @natrevclinoncol.bsky.social

📌ctDNA helps uncover resistance mechanisms
📌Standardized protocols are crucial for improving applications
📌ctDNA + tissue provides a more comprehensive view

nature.com/articles/s41...

@christianrolfo.bsky.social @osucccjames.bsky.social
rolfolab.bsky.social
Don’t miss this chance to contribute!
robertoboreamd.bsky.social
Now you can find the link to complete our @islb.info survey in the @oncoalert.bsky.social newsletter! 📨

It only takes 5 min to help us understand how LB 🩸 is reshaping clinical practice worldwide!

bit.ly/43JzN03

@christianrolfo.bsky.social @rolfolab.bsky.social @weoncologists.bsky.social
rolfolab.bsky.social
Great opportunity to gain valuable insights into METex14 skipping NSCLC! 🎦
robertoboreamd.bsky.social
Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology

@rolfolab.bsky.social @oncoalert.bsky.social
rolfolab.bsky.social
Congratulations Roberto! Well deserved! @osucccjames.bsky.social
robertoboreamd.bsky.social
Honored to be among the winners of the #TexasLung25 Poster Competition! 🎉 Grateful for the opportunity to share my research and contribute to the future of #lungcancer!
@christianrolfo.bsky.social @rolfolab.bsky.social @stephenvliu.bsky.social @osucccjames.bsky.social

➡️ hubs.la/Q03bqnlB0
Reposted by RolfoLab
robertoboreamd.bsky.social
The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer!

@christianrolfo.bsky.social @rolfolab.bsky.social
@osucccjames.bsky.social
#HER2 #IHC #Targettherapy
oncoalert.bsky.social
JOIN US for a discussion on HER2🧬testing & evolving role of IHC🔬 in hashtag#LungCancer & hashtag#OvarianCancer

REGISTER HERE👇👇
buff.ly/7F6ztd4

JOIN US TUESDAY MARCH 11, 2025
Reposted by RolfoLab
robertoboreamd.bsky.social
✨ Insightful presentation by @manelesteller.bsky.social from
@carrerasijc.bsky.social at @osuwexmed.bsky.social
Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊
@christianrolfo.bsky.social @rolfolab.bsky.social